Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141890

Published: 2020

Journal Articles

Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-138478

Published: 2020

Journal Articles

Viral Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: Benefits and Risks for Disease Relapse

Sandrine Loron, MD, Mohamad Sobh, PharmD, Fiorenza Barraco, MD, Xavier Thomas, MD, Sophie Ducastelle, MD, Myriam Renault, CRA, Florence Ader, MD, Emilie Frobert, MD, Franck-Emmanuel Nicolini, MD PhD, Hélène Labussière, MD, Mauricette Michallet, MD PhD

Blood (2018) 132 (Supplement 1): 2140.

https://doi.org/10.1182/blood-2018-99-118249

Published: 2018

Journal Articles

Addition of More Immunosuppressive Drugs As Graft-Versus-Host Disease (GVHD) Prophylaxis Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Fiorenza Barraco, MD, Xavier Thomas, MD PhD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle, MD, Myriam Renault, CRA, Nathalie Tedone, CRA, Helene Labussiere, MD, Franck-Emmanuel Nicolini, MD PhD

Blood (2016) 128 (22): 5786.

https://doi.org/10.1182/blood.V128.22.5786.5786

Published: 2016

Journal Articles

Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Florence Ranchon, PharmD, Sandrine Leroy, MD, Fiorenza Barraco, MD, Xavier Thomas, MD PhD, Marie Balsat, MD, Caroline Lejeune, MD, Sophie Ducastelle, MD, Bruno Lina, MD PhD, Florence Morfin, MD, Myriam Renault, CRA, Florence Ader, MD, Catherine Rioufol, PharmD, Helene Labussiere, MD, Franck-Emmanuel Nicolini, MD PhD

Blood (2016) 128 (22): 3695.

https://doi.org/10.1182/blood.V128.22.3695.3695

Published: 2016

Journal Articles

Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?

Etienne Paubelle, MD PhD, Sophie Ducastelle, MD, Helene Labussiere, MD, Franck E. Nicolini, MD PhD, Fiorenza Barraco, MD, Adriana Plesa, Gilles A. Salles, Eric Wattel, MD PhD, Xavier Thomas, MD PhD

Blood (2016) 128 (22): 4003.

https://doi.org/10.1182/blood.V128.22.4003.4003

Published: 2016

Journal Articles

Preventive Versus Curative Platelet Transfusion Strategies in the Treatment of Acute Myeloid Leukemia Patients: A Comparative Study

Aude Charbonnier, MD PhD, Michel Raba, MD, Patrick Ladaique, Laurence Augey, MD, Lilian Laborde, Jeremy Monfray, CRA, Carine Champigneulle, CRA, Mohamad Sobh, Pharm.M., Helene Labussiere-Wallet, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Xavier Thomas, MD PhD, Anne Etienne, MD, Thomas Prebet, MD PhD, Evelyne D'Incan, MD, Jerome Rey, MD, Franck E. Nicolini, MD PhD, Norbert Vey, MD, Mauricette Michallet, MD PhD

Blood (2014) 124 (21): 4288.

https://doi.org/10.1182/blood.V124.21.4288.4288

Published: 2014

Journal Articles

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Marie Y. Detrait, MD, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valentina Bozzoli, MD, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3892.

https://doi.org/10.1182/blood.V124.21.3892.3892

Published: 2014

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Acute Myeloid Leukemia

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Jeremy Monfray, CRA, Hélène Labussière-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valerie Dubois, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 2542.

https://doi.org/10.1182/blood.V124.21.2542.2542

Published: 2014

Journal Articles

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Yesim G. Dargaud, MDPhD, Marc Fouassier, MD, Sophie Ducastelle, MD, Philippe Moreau, MD, Charles Dumontet, MD PhD, Mauricette Michallet, MD PhD, Jean-Claude Bordet, Claude Negrier, MD PhD

Blood (2014) 124 (21): 2037.

https://doi.org/10.1182/blood.V124.21.2037.2037

Published: 2014

Journal Articles

Impact of Single or Associated CMV, EBV and BK Virus Reactivation Early after Allogeneic Hematopoietic Stem Cell Transplantation on Relapse Incidence

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Sandrine Leroy, MD, Fiorenza Barraco, MD, Xavier Thomas, MD PhD, Sophie Ducastelle, MD, Bruno Lina, MD PhD, Florence Morfin, MD, Florence Ader, MD, Emilie Frobert, MD, Franck E. Nicolini, MD PhD, Anne-Sophie Michallet, MD PhD

Blood (2014) 124 (21): 1428.

https://doi.org/10.1182/blood.V124.21.1428.1428

Published: 2014

Journal Articles

Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Mohamed Elhamri, PhD, Jeremy Monfray, CRA, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Adriana Plesa, MD, Valerie Dubois, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3691.

https://doi.org/10.1182/blood.V124.21.3691.3691

Published: 2014

Journal Articles

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M, Helene Labussiere, MD, Lila Gilis, MD, Fiorenza Barraco, MD, Madeleine Etienne, CRA, Oriane Le Borgne, CRA, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Sophie Ducastelle, MD, Xavier Thomas, MD

Blood (2013) 122 (21): 2721.

https://doi.org/10.1182/blood.V122.21.2721.2721

Published: 2013

Journal Articles

Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation For High Risk Acute Myeloid Leukemia Patients In First Complete Remission: A Prospective Pilot Study

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Marie Y. Detrait, MD, Helene Labussiere, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed El Hamri, PhD, Lila Gilis, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valentina Bozzoli, MD, Franck E. Nicolini, MD, PhD, Xavier Thomas, MD

Blood (2013) 122 (21): 2162.

https://doi.org/10.1182/blood.V122.21.2162.2162

Published: 2013

Journal Articles

Intravenous Once-Daily BuCy 2 With Pharmacokinetic (PK)-Guided Dose Adjustment As Conditioning Regimen For AML Patients In First Complete Remission

Felipe Suarez, MD, Philippe Bourget, PhD, Emilio Paolo Alessandrino, MD, Mario Regazzi, PhD, Gérard Socié, MD, PhD, Mauricette Michallet, MD, PhD, Jérôme Guitton, PHD, Sebastien Wittnebel, MD, Angelo Paci, PHD, Didier Blaise, MD, Bénédicte Devictor, PHD, Ana Berceanu, MD, Véronique Kemmel, PHD, Jorge Sierra, MD, PhD, Maria Estela Moreno Martinez, PHD, Ambroise Marcais, MD, Alexandre Amin, PHD, Anna Amelia Colombo, MD, Francesco Ripamonti, MD, de Latour Régis Peffault, MD, Nathalie Dhedin, MD, Alienor Xhaard, MD, Hélène Labussière-Wallet, MD, Franck E Nicolini, MD, PhD, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Xavier Thomas, MD, Jean-Henri Bourhis, MD, PhD, Gonzalo Ferrini, PHD, Sabine Furst, MD, Bruno Lioure, MD, Rodrigo Martino, MD, PhD, Mireia Riba, PH, Anna Feliu, PHD, Carole Levrault, Marcello Riggi, MD, PhD, Christine Ta Thanh Minh, MD

Blood (2013) 122 (21): 4566.

https://doi.org/10.1182/blood.V122.21.4566.4566

Published: 2013

Journal Articles

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

Florence Beckerich, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Adriana Plesa, MD, Valerie Dubois, MD, Isabelle Mollet, Helene Labussiere, MD, Lila Gilis, MD, Sophie Ducastelle, MD, Oriane Le Borgne, CRA, Jeremy Monfray, CRA, Fiorenza Barraco, MD, Isabelle Tigaud, MD, Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2013) 122 (21): 4639.

https://doi.org/10.1182/blood.V122.21.4639.4639

Published: 2013

Journal Articles

Significant Impact Of Iron Chelation After Allogeneic Hematopoetic Stem Cell Transplantation On Disease Recurrence: Potential Anti-Leukemic Activity

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Helene Labussiere, MD, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Lila Gilis, MD, Richard Cohen, Tech., Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Colette Chapuis-Cellier, MD

Blood (2013) 122 (21): 180.

https://doi.org/10.1182/blood.V122.21.180.180

Published: 2013

Journal Articles

Oral Mucositis After Allogeneic Hematopoietic Stem Cell Transplantation: Important Impact Of The Presence Of Aciclovir-Resistant Herpes Simplex Virus (HSV-1) On Its Occurrence

Emilie Frobert, MD, Mohamad Sobh, Pharm.M., Florence Morfin, MD, Helene Labussiere, MD, Sophie Ducastelle, MD, Lila Gilis, MD, Fiorenza Barraco, MD, Vanessa Escuret, MD, Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Bruno Lina, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2013) 122 (21): 1048.

https://doi.org/10.1182/blood.V122.21.1048.1048

Published: 2013

Journal Articles

Flamsa-RIC Sequential Regimen in High Risk CR1 AML Patients: Preliminary Results From a Pilot Study

Blood (2012) 120 (21): 4549.

https://doi.org/10.1182/blood.V120.21.4549.4549

Published: 2012

Journal Articles

Iron Overload in Patients with Hematological Disorders Undergoing Allogeneic HSCT: Unrevealed Implication in Different Outcomes

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Stéphane Morisset, Stat., Hélène Labussière-Wallet, MD, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Youcef Chelghoum, MD, Anne Cordonnier, Richard Cohen, Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Colette Chapuis-Cellier, MD

Blood (2012) 120 (21): 4527.

https://doi.org/10.1182/blood.V120.21.4527.4527

Published: 2012

NARROW

Impact of DNMT3a Status on Post Induction NPM1 MRD Predictive Value on Survival in Elderly AML Patients Treated Intensively

Daratumumab after Allogeneic Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Safety and Efficacy. a Retrospective Study from the Cmwp EBMT

Viral Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: Benefits and Risks for Disease Relapse

Addition of More Immunosuppressive Drugs As Graft-Versus-Host Disease (GVHD) Prophylaxis Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors

Epstein-Barr Virus (EBV) Reactivation, Its Treatment with Rituximab and Their Impact on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies

Fractionated Gemtuzumab Ozogamicin Combined with Intermediate-Dose Cytarabine and Daunorubicin As Salvage Therapy in Very High Risk AML Patients: A Bridge to Reduced Intensity Conditioning Transplant?

Preventive Versus Curative Platelet Transfusion Strategies in the Treatment of Acute Myeloid Leukemia Patients: A Comparative Study

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Acute Myeloid Leukemia

The Challenge of Myeloma-Related Thromboembolic Disease: Can Thrombin Generation Assay May Detect Disease-Related Hypercoagulability?

Impact of Single or Associated CMV, EBV and BK Virus Reactivation Early after Allogeneic Hematopoietic Stem Cell Transplantation on Relapse Incidence

Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation For High Risk Acute Myeloid Leukemia Patients In First Complete Remission: A Prospective Pilot Study

Intravenous Once-Daily BuCy 2 With Pharmacokinetic (PK)-Guided Dose Adjustment As Conditioning Regimen For AML Patients In First Complete Remission

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

Significant Impact Of Iron Chelation After Allogeneic Hematopoetic Stem Cell Transplantation On Disease Recurrence: Potential Anti-Leukemic Activity

Oral Mucositis After Allogeneic Hematopoietic Stem Cell Transplantation: Important Impact Of The Presence Of Aciclovir-Resistant Herpes Simplex Virus (HSV-1) On Its Occurrence

Flamsa-RIC Sequential Regimen in High Risk CR1 AML Patients: Preliminary Results From a Pilot Study

Iron Overload in Patients with Hematological Disorders Undergoing Allogeneic HSCT: Unrevealed Implication in Different Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only